Rankings
▼
Calendar
ALKS Q1 2024 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$350M
+21.8% YoY
Gross Profit
$292M
83.3% margin
Operating Income
$43M
12.4% margin
Net Income
$37M
10.5% margin
EPS (Diluted)
$0.21
QoQ Revenue Growth
-7.2%
Cash Flow
Operating Cash Flow
$21M
Free Cash Flow
$13M
Stock-Based Comp.
$33M
Balance Sheet
Total Assets
$2.1B
Total Liabilities
$869M
Stockholders' Equity
$1.3B
Cash & Equivalents
$421M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$350M
$288M
+21.8%
Gross Profit
$292M
$229M
+27.2%
Operating Income
$43M
-$11M
+494.7%
Net Income
$37M
-$42M
+188.0%
Revenue Segments
Product
$234M
50%
Vivitrol
$98M
21%
Aristada And Aristada Initio
$79M
17%
L Y B A L V I
$57M
12%
← FY 2024
All Quarters
Q2 2024 →